Welcome to our dedicated page for PHIBRO ANIMAL HEALTH SEC filings (Ticker: PAHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PHIBRO ANIMAL HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PHIBRO ANIMAL HEALTH's regulatory disclosures and financial reporting.
Phibro Animal Health reported that BFI Co., LLC, an entity associated with President and CEO Jack Bendheim, sold a total of 21,120 shares of Class A Common Stock in open‑market transactions at weighted average prices around $54–$56 per share. These sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025. After the sales, BFI Co., LLC held 95,880 Class A shares, while Jack Bendheim directly held 16,840 Class A shares.
Phibro Animal Health Corp’s CEO-linked entity BFI Co., LLC converted 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock and then sold 21,120 Class A shares in open-market transactions from April 14–16 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices ranged from about $53.80 to $59.83. After these trades, BFI held 117,000 Class A shares indirectly, while Jack Bendheim also directly held 16,840 Class A shares, showing that a substantial position remains after these planned sales.
Phibro Animal Health Corporation reported that board member Joyce J. Lee, a Class II Director, informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The company stated that Ms. Lee’s resignation is not due to any disagreement regarding its operations, policies, or practices.
FMR LLC reported beneficial ownership of 2,173,126.20 shares of PHIBRO ANIMAL HEALTH CORP Class A common stock, representing 10.5% of the class as of 03/31/2026. The filing states FMR has sole voting power over 2,171,187 shares and sole dispositive power over 2,173,126.20 shares. The Schedule 13G notes some shares are held on behalf of other persons and refers to Exhibit 99 for a 13d-1(k)(1) agreement.
Phibro Animal Health (PAHC) insider activity centers on BFI Co., LLC, an entity associated with President and CEO Jack Bendheim. BFI Co., LLC reported open-market sales totaling 14,080 shares of Class A Common Stock on March 30 and March 31 under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported weighted average sale prices were about $53.54 and $54.31 per share on March 30 and about $53.87 and $54.35 per share on March 31. After these transactions, BFI Co., LLC holds 38,120 shares indirectly, while Bendheim directly holds 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership beyond his pecuniary interest.
Phibro Animal Health Corp (PAHC) filing shows The Vanguard Group filed Amendment No. 13 to its Schedule 13G/A stating it beneficially owns 0% of Phibro Animal Health Corp common stock as reported in the form. The amendment explains an internal realignment on 01/12/2026 that caused certain Vanguard subsidiaries and business divisions to report ownership separately.
Phibro Animal Health Corp reported that BFI Co., LLC, an entity over which President and CEO Jack Bendheim exercises voting and dispositive power, sold a total of 21,120 shares of Class A Common Stock in open-market transactions on March 24–26, 2026.
The weighted average sale prices ranged from about $52.8772 to $57.1702 per share. Following these indirect sales, BFI Co., LLC held 52,200 Class A shares, while Bendheim directly held 16,840 shares. The sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-scheduled rather than discretionary.
Phibro Animal Health insider activity shows an entity associated with President and CEO Jack Bendheim selling Class A Common Stock. BFI Co., LLC sold a total of 22,880 shares in open-market transactions on March 17–19 at reported weighted average prices between $51.6590 and $53.6436 per share, under a Rule 10b5-1 trading plan adopted on December 11, 2025. Following these sales, BFI Co., LLC held 73,320 shares indirectly, while Jack Bendheim also directly held 16,840 shares. Bendheim may be deemed to share voting and investment power over BFI’s holdings but disclaims beneficial ownership except for his pecuniary interest.
Phibro Animal Health insider activity shows entity BFI Co., LLC, which is associated with President and CEO Jack Bendheim, converting and selling shares. BFI converted 100,000 shares of Class B Common Stock into the same number of Class A shares and then sold 5,280 Class A shares at a weighted average price of $48.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, indicating it was scheduled in advance. Following these transactions, BFI held 96,200 Class A shares indirectly, while Bendheim directly held 16,840 Class A shares, and BFI continued to hold 19,596,034 Class B shares, which remain convertible into Class A on a one-for-one basis.
Phibro Animal Health Corporation submitted a Form 144 notice indicating proposed sales of Class A Common Stock by an affiliate, with multiple transactions listed through February 2026. The excerpt includes numerous brokered sell entries by BFI Co. LLC, including large single-day totals such as 58,042 shares and 49,280 shares.
The filing lists transaction dates and per‑trade share counts and proceeds; the excerpt does not state aggregate registered offering treatment or who receives proceeds.